Evidence map›Paper›PMID 34396450›Full record

ArticleMolecular medicine reports2021

Protective effects of metformin against myocardial ischemia‑reperfusion injury via AMPK‑dependent suppression of NOX4.

Yan Shi, Shu-Ai Hou

RetractedErratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yan ShiDepartment of Critical Care Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China.
Shu-Ai HouDepartment of Critical Care Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China.
People’s Hospital of Rizhao · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients. However, its specific mechanism has not been determined. Using a rat model of myocardial ischemia‑reperfusion injury (MIRI), it was observed that metformin significantly reduced infarct size, and decreased the levels of plasma lactate dehydrogenase and creatine kinase‑MB form. A TTC‑Evans blue staining was used to detect the infarct size and MTT assay was used to evaluate the cell viability. TUNEL assay was performed to evaluate apoptosis. Furthermore, 4‑hydroxynonenal was detected by immunohistochemical staining. mRNA expression levels were detected by reverse transcription‑quantitative PCR; protein expression levels were detected by immunoblotting. When treated with metformin, the number of TUNEL‑positive cells was significantly decreased. Reduced 4HNE immunoreactivity was observed in metformin‑treated rats as determined via immunohistochemistry. Furthermore, NADPH oxidase 4 (NOX4) was downregulated by metformin at both the mRNA and protein levels, and adenosine 5'‑monophosphate‑activated protein kinase (AMPK) phosphorylation was increased by metformin. In a primary myocardial hypoxia‑reoxygenation cell model, metformin increased the viability of cardiomyocytes and reduced the content of malondialdehyde. It was also found that metformin upregulated the phosphorylation of AMPK and decreased the expression of NOX4. Furthermore, pre‑treatment with AMPK inhibitor compound‑C could block the effect of metformin, indicated by increased NOX4 compared with metformin treatment alone. These results suggested that metformin was capable of reducing the oxidative stress injury induced by MIRI. In conclusion, the present study indicated that metformin activated AMPK to inhibit the expression of NOX4, leading to a decrease in myocardial oxidative damage and apoptosis, thus alleviating reperfusion injury.

Indexed as

AMP-Activated Protein KinasesAnimalsApoptosisCell HypoxiaCell SurvivalCreatine Kinase, MB FormMaleMetforminMyocardial InfarctionMyocardial Reperfusion InjuryMyocardiumMyocytes, CardiacNADPH Oxidase 4Oxidative StressPhosphorylationRatsAMP-Activated Protein KinasesCreatine Kinase, MB FormMetforminNADPH Oxidase 4Nox4 protein, ratRNA, Small Interferingadenosine 5'‑monophosphate‑activated protein kinaseapoptosismetforminmyocardial reperfusion injuryNADPH oxidase 4oxidative stress

Identifiers

PMID34396450
PMCPMC8383039
OpenAlexW3191218851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.